Skip to main content
SpringerLink
Log in

Atrial Fibrillation and Heart Failure Syndromes

  • Chapter
  • First Online:
Heart Failure in Clinical Practice

  • 1626 Accesses

Abstract

Heart failure syndromes are characterized by acute and chronic symptomatic clinical presentations of variable etiology. Definitions of heart failure in many studies and surveys vary enormously. Most heart failures involve failure of cardiac mechanics resulting in reduced stroke volume or cardiac work, which in turn occur as a consequence of several processes. Heart failure syndromes are frequently characterized as primarily linked to either systolic or diastolic ventricular dysfunction but most often involve combinations of both to result in elevated pulmonary pressure and pulmonary edema causing breathlessness and exercise limitation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 1994;271:840-844.

    Article  PubMed  CAS  Google Scholar 

  2. Cleland JGF, Swedberg K, Follath F, et al. The Euro Heart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24:442-463.

    Article  PubMed  CAS  Google Scholar 

  3. Camm AJ, Savalieva I. Atrial fibrillation: advances and perspectives. Dialog Cardiovasc Med. 2003;8:183-202.

    Google Scholar 

  4. Dries DL, Exner DV, Gersch BJ, et al. Atrial fibrillation is associated with an increased risk for mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol. 1998;32:695-703.

    Article  PubMed  CAS  Google Scholar 

  5. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillatio n in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149:548-557.

    Article  PubMed  CAS  Google Scholar 

  6. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920-2925.

    Article  PubMed  Google Scholar 

  7. Mathew J, Hunsberger S, Fleg J, et al. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest. 2000;2000:914-922.

    Article  Google Scholar 

  8. Baldasseroni S, Opasisch C, Giorni M, et al. Left bundle branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients withcongestive heart failure. Am Heart J. 2002;143:398-405.

    Article  PubMed  Google Scholar 

  9. Baldasseroni S, De Biase L, Fresco C, et al. Italian Network on Congestive Heart Failure. Cumulative effect of complete left bundle-branch block and chronic atrial fibrillation on 1-year mortality and hospitalization in patients with congestive heart failure. A report from the Italian network on congestive heart failure (in-CHF database). Eur Heart J. 2002;23:1692-1698.

    PubMed  CAS  Google Scholar 

  10. Pai RG, Varadarajan P. Prognostic significance of atrial fibrillation is a function of left ventricular ejection fraction. Clin Cardiol. 2007;30:349-354.

    Article  PubMed  Google Scholar 

  11. Santinelli V, et al. Atrial fibrillation progression in patients with and without lone atrial fibrillation. A Five Year Prospective Follow-Up Study (abstr). J Am Coll Cardiol. 2008;51(suppl A):A6.

    Google Scholar 

  12. Keating RJ, Gersh B, Hodge D. Effect of atrial fibrillation pattern on survival in a community-based cohort. Am J Cardiol. 2005;96:1420-1424.

    Article  PubMed  Google Scholar 

  13. Miyasaka Y, Barnes ME, Gersh BJ, et al. Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades. Eur Heart J. 2006;27:936-941.

    Article  PubMed  Google Scholar 

  14. Shinbane JS, Wood MA, Jensen DN, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709-715.

    Article  PubMed  CAS  Google Scholar 

  15. Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol Heart Circ Physiol. 1991;261:H301-H318.

    Google Scholar 

  16. Tomita M et al. Changes in left ventricular volume, mass, and function during the development and regression of supraventricular tachycardia-induced cardiomyopathy. Disparity between recovery of systolic versus diastolic function Circulation. 1991;83:635-644.

    CAS  Google Scholar 

  17. Ehrlich JR et al. Atrial fibrillation and congestive heart failure: specific considerations at the intersection of the two common and important cardiac disease sets. J Cardiovasc Electrophysiol. 2002;13:399-405.

    Article  PubMed  Google Scholar 

  18. Li D et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation. 2000;101:2631-2638.

    Article  PubMed  CAS  Google Scholar 

  19. Li D et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999;100:87-95.

    Article  PubMed  CAS  Google Scholar 

  20. Tsang TS et al. Left atrial volume: important risk marker of incident atrial fibrillation in 1, 655 older men and women. Mayo Clin Proc. 2001;76:467-475.

    Article  PubMed  CAS  Google Scholar 

  21. Tsang TS et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002;40:1636-1644.

    Article  PubMed  Google Scholar 

  22. Amir O et al. Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure. Am J Cardiol. 2008;102:326-329.

    Article  PubMed  CAS  Google Scholar 

  23. Tsang TS et al. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol. 2002;90:1284-1289.

    Article  PubMed  Google Scholar 

  24. Li D et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;104:2608-2614.

    Article  PubMed  CAS  Google Scholar 

  25. Mattioli AV, Bonatti S, Monopoli D, Zennaro M, Mattioli G. Influence of regression of left ventricular hypertrophy on left atrial size and function in patients with moderate hypertension. Blood Press. 2005;14:273-278.

    Article  PubMed  Google Scholar 

  26. Tsang TS, Barnes ME, Abhayaratna WP, et al. Effects of quinapril on left atrial structural remodeling and arterial stiffness. Am J Cardiol. 2006;97:916-920.

    Article  PubMed  CAS  Google Scholar 

  27. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388-1393.

    Article  PubMed  CAS  Google Scholar 

  28. Brooks WW, Bing OH, Robinson KG, Slawsky MT, Chaletsky DM, Conrad CH. Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation. 1997;96:4002-4010.

    Article  PubMed  CAS  Google Scholar 

  29. Weber KT, Brilla CG, Campbell SE, Guarda E, Zhou G, Sriram K. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol. 1993;88(suppl 1):107-124.

    PubMed  CAS  Google Scholar 

  30. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112:1428-1434.

    Article  PubMed  CAS  Google Scholar 

  31. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110:1103-1107.

    Article  PubMed  CAS  Google Scholar 

  32. Xu ZG, Lanting L, Vaziri ND, et al. Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type 1 receptor blockade. Circulation. 2005;111:1962-1969.

    Article  PubMed  CAS  Google Scholar 

  33. Ferrari R, Cicchitelli G, Merli E, Andreadou I, Guardigli G. Metabolic modulation and optimization of energy consumption in heart failure. Med Clin North Am. 2003;87:493; xiii.

    Google Scholar 

  34. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 2003;41:2197-2204.

    Article  PubMed  CAS  Google Scholar 

  35. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation. 2000;101:2612-2617.

    Article  PubMed  CAS  Google Scholar 

  36. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712-719.

    Article  PubMed  CAS  Google Scholar 

  37. Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;152:86-92.

    Article  PubMed  Google Scholar 

  38. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100:376-380.

    Article  PubMed  CAS  Google Scholar 

  39. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 2003;107:2926-2931.

    Article  PubMed  Google Scholar 

  40. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832-1839.

    Article  PubMed  CAS  Google Scholar 

  41. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J. 2006;152:217-222.

    Article  PubMed  CAS  Google Scholar 

  42. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Eng J Med. 2002;347:1825-1833.

    Google Scholar 

  43. Van Gelder IC et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Eng J Med. 2002;347:1834-1840.

    Article  Google Scholar 

  44. Roy D et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Eng J Med. 2008;358:2667-2777.

    Article  CAS  Google Scholar 

  45. Hunt SA et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College ofCardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and theInternational Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154-e235.

    Article  PubMed  Google Scholar 

  46. Olshansky B, et al.; The AFFIRM investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43:1201-1208.

    Google Scholar 

  47. Khand AU et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 2003;42:1944-1951.

    Article  PubMed  CAS  Google Scholar 

  48. Delle Karth G et al. Amiodarone versus diltiazem for rate control in critically ill patients with tachyarrhythmias. Crit Care Med. 2001;29:1149-1153.

    Article  PubMed  CAS  Google Scholar 

  49. Fuster V et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/AmericanHeart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e354.

    Google Scholar 

  50. Brignole M et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation. 1998;98:953-960.

    Article  PubMed  CAS  Google Scholar 

  51. Weerasooriya R et al. The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol. 2003;41:1697-1702.

    Article  PubMed  Google Scholar 

  52. The AFFIRM investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation. 2004;109:1509-1513.

    Article  Google Scholar 

  53. Roy D et al. Amiodarone to prevent recurrence of atrial fibrillation. N Eng J Med. 2000;342:913-920.

    Article  CAS  Google Scholar 

  54. Deedwania PC et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHFSTAT). Circulation. 1998;98:2574-2579.

    Article  PubMed  CAS  Google Scholar 

  55. Touboul P et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24:1481-1487.

    Article  PubMed  CAS  Google Scholar 

  56. Hohnloser SH, et al. A placebo-controlled, double-blind, parallel arm trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/ atrial flutter (AF/AFL). Heart Rhythm Society 2008 Scientific Sessions: 2008. Heart Rhythm Society 2008 Scientific Sessions; 2008.

    Google Scholar 

  57. Kober L et al. Increased mortality after dronedarone therapy for severe heart failure. N Eng J Med. 2008;358:2678-2687.

    Article  Google Scholar 

  58. Pedersen OD et al. Efficacy of dofetilide in the treatment of atrial fibrillation–flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality On Dofetilide (DIAMOND) substudy. Cicrulation. 2001;104:292-296.

    Article  CAS  Google Scholar 

  59. Torp-Pedersen C et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Eng J Med. 1999;341:857-865.

    Article  CAS  Google Scholar 

  60. Connolly SJ et al. Doseeresponse relations of azimilide in the management of symptomatic, recurrent atrial fibrillation. Am J Cardiol. 2001;88:974-979.

    Article  PubMed  CAS  Google Scholar 

  61. Pratt CM et al. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol. 2004;43:1211-1216.

    Article  PubMed  CAS  Google Scholar 

  62. Camm AJ et al. Azimilide Post Infarct Evaluation (ALIVE): azimilide does not affect mortality in post-myocardial infarction patients. Circulation. 2004;109:990-996.

    Article  PubMed  Google Scholar 

  63. Corley SD et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Cicrulation. 2004;109:1509-1513.

    Article  Google Scholar 

  64. Oral H et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation. 2002;105:1077-1081.

    Article  PubMed  Google Scholar 

  65. Pappone C et al. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation. 2001;104:2539-2544.

    Article  PubMed  CAS  Google Scholar 

  66. Gentlesk PJ et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18:9-14.

    Article  PubMed  Google Scholar 

  67. Hsu LF et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Eng J Med. 2004;351:2373-2383.

    Article  CAS  Google Scholar 

  68. Kay GN et al. The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. J Interv Card Electrophysiol. 1998;2:121-135.

    Article  PubMed  CAS  Google Scholar 

  69. Ozcan C et al. Significant effects of atrioventricular node ablation and pacemaker implantation on left ventricular function and long-term survival in patients with atrial fibrillation and left ventricular dysfunction. Am J Cardiol. 2003;92:33-37.

    Article  PubMed  Google Scholar 

  70. Doshi RN et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol. 2005;16:1160-1165.

    Article  PubMed  Google Scholar 

  71. Khan MN, et al. Late-Breaking Clinical Trial abstracts from the American Heart Association’s Scientific Sessions 2006: Randomized Controlled Trial of pulmonary vein antrum isolation vs. AV node ablation with bi-ventricular pacing for treatment of atrial fibrillation in patients with congestive heart failure (PABA CHF). Circulation. 2006;114:abstract.

    Google Scholar 

  72. Khan MN, et al. Progression of atrial fibrillation in the pulmonary vein antrum isolation vs. AV node ablation with biventricular pacing for treatment of atrial fibrillation patients with Congestive Heart Failure Trial (PABA-CHF). Heart Rhythm. 2006;3:abstract.

    Google Scholar 

  73. Kamath S et al. Platelet activation, haemorheology and thrombogenesis in acute atrial fibrillation: a comparison with permanent atrial fibrillation. Heart. 2003;89:1903-1905.

    Article  Google Scholar 

  74. Hart RG et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501.

    PubMed  CAS  Google Scholar 

  75. Baker DW, et al. Management of heart failure. IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. J Am Med Assoc. 1994;272:1614-1618.

    Google Scholar 

  76. Lip GYL, Gibbs CR. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. QJM. 2002;95:461-468.

    Article  PubMed  CAS  Google Scholar 

  77. Wolf PA, Kannel WB, McNamara PM. Occult impaired cardiac function, congestive heart failure and risk of thrombotic stroke: The Framingham Study. Neurology. 1970;20:373.

    Article  PubMed  CAS  Google Scholar 

  78. Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke. The Framingham Study. JAMA. 1983;250:2942-2946.

    Article  PubMed  CAS  Google Scholar 

  79. Hays AG, Sacco RL, Rundek T, et al. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke. 2006;37:1715-1719.

    Article  PubMed  Google Scholar 

  80. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Eng J Med. 1997;336:251-257.

    Article  CAS  Google Scholar 

  81. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from three clinical trials. Arch Intern Med. 1998;158:1316-1320.

    Article  Google Scholar 

  82. The CONSENSUS Trial Study Group. Effect of Enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Eng J Med. 1987;316:1429-1435.

    Google Scholar 

  83. Al-Khadra AS, Salem DN, Rand WM, et al. Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol. 1998;31:749-753.

    Article  PubMed  CAS  Google Scholar 

  84. Dunkman DB, Johnson GR, Carson PE, et al. Incidence of thromboembolic events in congestive heart failure. Circulation. 1993;87(suppl 6):94-101.

    Google Scholar 

  85. Falk RH, Pollak A, Tandon PK, et al. The effect of warfarin on prevalence of stroke in patients with severe heart failure. J Am Coll Cardiol. 1993;21:218.

    Google Scholar 

  86. Redfield MM. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194-202.

    Article  PubMed  Google Scholar 

  87. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948-1955.

    Article  PubMed  CAS  Google Scholar 

  88. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-781.

    Article  PubMed  CAS  Google Scholar 

  89. Klapholz M, Maurer M, Lowe AM, et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol. 2004;43:1432-1438.

    Article  PubMed  Google Scholar 

  90. Cleland JG, Findlay I, Jafri S, et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomised trial comparing antithrombotic strategies for patients with heart failure. Am Heart J. 2004;148:157-164.

    Article  PubMed  CAS  Google Scholar 

  91. Massie BM, Krol WF, Ammon SE, et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail. 2004;10:101-112.

    Article  PubMed  CAS  Google Scholar 

  92. Cokkinos DV, Haralabopoulos GC, Kostis JB, et al. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail. 2006;8:428-432.

    Article  PubMed  CAS  Google Scholar 

  93. Freemantle N, Tharmanathan P, Calvert MJ, et al. Cardiac resynchronisation for patients with heart failure due to left ventricular systolic dysfunction – a systematic review and meta analysis. Eur J Heart Fail. 2006;8:433-440.

    Article  PubMed  CAS  Google Scholar 

  94. Gasparini M, Regoli F. Trials of CRT in atrial fibrillation and atrial rhythm management issues. In: Yu C-M, Hayes DL, Auricchio A, eds. Cardiac Resynchronization Therapy. 2nd ed. London: Blackwell; 2008:277-289 [chapter 15].

    Google Scholar 

  95. Hayes DL, Yu C-M. Ongoing trials to further shape the future of CRT. In: Yu C-M, Hayes DL, Auricchio A, eds. Cardiac Resynchronization Therapy, 2nd ed. London: Blackwell; 2008:290-300 [chapter 16].

    Google Scholar 

  96. Braunschweig F, Mortensen PT, Gras D, et al. Monitoring of physical activity and heart rate variability in patients with chronic heart failure using cardiac resynchronization devices. Am J Cardiol. 2005;95:1104-1107.

    Article  PubMed  Google Scholar 

  97. Savelieva I, Camm AJ. Atrial fibrillation and heart failure: natural history and pharmacological treatment. Europace. 2004;5:S5-S19.

    Article  PubMed  Google Scholar 

  98. Morrison TB, Bunch TJ, Gersch BJ. Pathophysiology of concomitant atrial fibrillation and heart failure: implications for management. Nature Clin Prac Cardiovasc Med. 2009;6:46-56.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Department of Medicine, City Hospital, Dudley Road, Birmingham, UK

    Robert J. MacFadyen

Authors
  1. Lynne Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory Y. H. Lip
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert J. MacFadyen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert J. MacFadyen .

Editor information

Editors and Affiliations

  1. Thorney Crescent 27, Battersea, London, SW11 3TT, United Kingdom

    Michael Y. Henein

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer London

About this chapter

Cite this chapter

Williams, L., Lip, G.Y.H., MacFadyen, R.J. (2010). Atrial Fibrillation and Heart Failure Syndromes. In: Henein, M. (eds) Heart Failure in Clinical Practice. Springer, London. https://doi.org/10.1007/978-1-84996-153-0_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-84996-153-0_16

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84996-152-3

  • Online ISBN: 978-1-84996-153-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation